AKTIS ONCOLOGY INC

AKTSNASDAQ

🏆 #2035 by market capUS Equity

$24.60▼ $0.18 (−0.73%)

Live

1h▼ 1.4%

24h▼ 0.7%

7d▲ 8.7%

14d▲ 10.3%

30d▼ 3.8%

1y—

🏦Market Cap

$1.31B

Small Cap

📈Revenue Growth (YoY)

+49.9%

High Growth

📊Gross Margin

-11.6%

Thin

💵FCF Margin

—

⚖️P/S Ratio

137.0x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $24.37 – $25.06
52-Week Range: $14.72 – $34.19
Volume: $2.35B
Avg Volume: $2.37B
Shares Outstanding: 53.4M
Next Earnings: Sep 16, 2026

Fundamentals Snapshot

Annual Revenue: $6M
Last Q Revenue: $3M
P/E Ratio: —
P/S Ratio: 137.0x
EPS (TTM): $-1.64
Dividend Yield: —

Why Investors Own AKTS

✓High-growth profile — revenue up +28.6% YoY with expanding US Equity exposure.
✓Healthy economics — 54% gross margin and 6% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$6M▲ +33.6% YoY

Gross Margin (TTM)

53.7%▲ +3.8% YoY

Operating Income (TTM)

$2M▲ +33.6% YoY

Free Cash Flow (TTM)

$409,311▲ +33.6% YoY

About AKTIS ONCOLOGY INC

Aktis Oncology, Inc. is a clinical-stage biotechnology firm dedicated to advancing targeted radiopharmaceutical therapies for cancer treatment. Their core innovation lies in a proprietary miniprotein radioconjugate platform, which enables the discovery and development of potent radiopharmaceutical therapies designed to precisely deliver tumor-killing radioisotopes. Among their pipeline candidates is Nectin-4, a miniprotein radioconjugate specifically engineered to treat locally advanced or metastatic urothelial cancer. Key programs also include AKY-1189, a radioconjugate engineered to target Nectin-4 expressing tumors across various indications such as metastatic urothelial cancer, breast cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and cervical cancer. Another significant therapy, AKY-2519, is under development to deliver radioisotopes to B7-H3 (CD276) expressing tumors, addressing prostate cancer, lung cancer, and other solid tumor types. Originally incorporated as HotKnot Therapeutics, Inc., the company officially rebranded to Aktis Oncology, Inc. in April 2020. Founded in 2020, Aktis Oncology maintains its headquarters in Boston, Massachusetts.

🦦